CSPC OUYI PHARMACEUTICAL CO., LTD.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-03-29
- Employees
- -
- Market Cap
- -
- Website
- http://www.e-cspc.com
Clinical Trials
22
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:7
Phase 2:7
Phase 3:8
Drug Approvals
40
PHILIPPINES:38
FDA:2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Phase 3
8 (36.4%)Phase 1
7 (31.8%)Phase 2
7 (31.8%)A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
Phase 3
Not yet recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XRDrug: Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XRDrug: Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XRDrug: Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XRDrug: Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 815
- Registration Number
- NCT07026968
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
Phase 3
Recruiting
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Dextromethorphan and Bupropion Sustained-Release TabletsDrug: Placebo
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 388
- Registration Number
- NCT06958692
- Locations
- 🇨🇳
Beijing Anding Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT06943950
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
Phase 3
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT06571461
A Phase II Study of SYHX1901 Tablets in the Treatment of Severe Alopecia Areata
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06562894
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found